Nervous Disorder TRIZ Cases

A glatiramer acetate depot sustains therapeutic release for PPMS or SPMS while reducing injection frequency and injection-site problems.

This case examines dosage forms and schedules for methylone, 2C-B, and MBDB in neuropsychiatric treatment with fewer interactions.

A buffered water-based ramipril solution balances pH, stability, solubility, and taste masking for easier oral dosing.

Fully human antibodies target Aβ42 and truncated isoforms, helping suppress CSF and brain amyloid accumulation.

Modified ring systems and substitutions improve RIP1 kinase selectivity for diseases involving inflammation and necroptotic cell death.

This case examines formula I retinoids using nitrogen and halogen substitutions to support genomic and non-genomic RAR activity.

This case examines tropane CCR5/CCL5 inhibitors, alone or with a statin, to target ME/CFS immune dysfunction.

Modular 4-alkoxypyrrolotriazine inhibitors target DYRK1A, addressing limited inhibitor availability and selective treatment needs.

iPS-derived neurons screen repositioned drugs for MFN1/MFN2 expression in CMT.

This case uses SGLT2 inhibitors to reduce reperfusion brain swelling independently of infarct size and support neurological recovery.

Epigenetic modulators induce a permissive chromatin state to reactivate the silenced FMR1 gene, reversing Fragile X Syndrome symptoms.

Stiripentol treats hyperammonemia by reducing ammonia levels and seizures, avoiding frequent dosing and side effects of phenylbutyrate.

A transdermal delivery system uses permeation enhancers to achieve bioequivalent plasma concentrations.

Modified phenolic TRPV1 agonists dissolve in aqueous injectables via hydrophilic groups, eliminating non-aqueous formulation complexity.

A donor nucleic acid cassette incorporates an effector gene into a target intron using non-homologous end joining.

Segmenting full-length dystrophin into functional modules reduces gene size while preserving membrane stability through targeted nNOS binding.

A multivalent fusion protein combines IL-2 and ST2 binding domains to selectively target regulatory T cells.

Hydrophobic interaction chromatography limits erenumab variants to maintain clinical efficacy against migraine.

A magnetic cell uses surface-bound particles to enable targeted movement and retention at a disease site.

Combining ivabradine with calcium channel blockers creates a synergistic therapeutic effect for angina treatment.

Downregulating PLD3 prevents axonal spheroid enlargement, restoring neural network function without amyloid removal.

Spexin polypeptides reduce alcohol consumption and promote cessation, addressing limited efficacy and side effects of current treatments.

Inflammatory cytokine biomarkers quantify suicide risk through objective serum analysis.

Fluorescence resonance energy transfer assay detects lipidated proteins using labeled binding agents, enabling rapid high-throughput analysis.

Analyzing peripheral blood biomarkers replaces invasive cerebrospinal fluid analysis to improve diagnostic accuracy while reducing patient pain.

Dual prime editing compositions target FMR1 gene sequences to excise expanded CGG repeats, restoring Fragile X Mental Retardation Protein expression.

Modified cyclic amine structures enhance 5-HT2A receptor binding affinity while reducing cardiovascular adverse effects.

Polyphenol analogs deliver neuroprotection through multi-target antioxidant and anti-inflammatory mechanisms.

Antrodia cinnamomea powder accelerates alcohol metabolism via enzymatic extraction, avoiding uric acid buildup from fructose.

Targeted acylation at specific lysine residues extends the half-life of calcitonin mimetics, enabling once-weekly administration instead of daily injections.

Pharmacological agents modulate specific genes and pathways to enhance nervous system plasticity.

Segmented antisense oligonucleotides reduce HTT-1A mRNA levels to mitigate neurodegeneration without affecting other huntingtin transcripts.

Citronellol and linalool from geranium oil inhibit acetylcholinesterase, addressing the lack of broad-spectrum treatments for neurodegenerative diseases.

A stem cell culture system uses a myosin II inhibitor to enhance cell survival and self-renewal.

Nepenthes enzymes degrade gluten into non-toxic fragments, eliminating the need for strict dietary restrictions.

Removing divalent metal co-factors from glycosyltransferase compositions preserves cell viability while enabling efficient enzymatic glycan modification.

Applying electromagnetic fields to metal nanoparticles increases neuron transdifferentiation efficiency for treating cerebral nerve diseases.

Oxybenzone in the topical ketoprofen emulsion prevents UV degradation and photoallergy.

A nutriprotective diet containing maple syrup polyphenolic extracts modulates cellular amino acid metabolism to deliver hepatoprotective effects.

Guanosine-rich DNA aptamers self-assemble into multimers that bind myelin, restoring insulation while avoiding antibody instability.

Segmented immediate and sustained release formulations address slow onset times while maintaining safety profiles for extended gaming sessions.

Combines palmitoylethanolamide with inorganic nitrate to modulate mast cell activity and enhance vasodilation.

Combining deuterated dextromethorphan with quinidine sulfate manages agitation in Alzheimer patients, addressing inadequate treatment options.

Souroubea and Platanus plant extracts lower cortisol concentrations via synergistic triterpenoids, addressing side effects of conventional anxiety treatments.

Adipose-derived stem cell secretome treats spinal cord injury by reducing inflammatory responses while promoting axonal regeneration through systemic delivery.

A merged nutritional composition of uridine, DHA, EPA, and choline slows hippocampal atrophy while simplifying treatment administration.

Administering DPP4 inhibitors during thrombectomy reduces inflammation and improves cognitive recovery outcomes.